Previous 10 | Next 10 |
Zai Lab (NASDAQ:ZLAB) announces that the Phase 3 PRIME study of Zeluja (niraparib) as maintenance therapy met its primary endpoint. Shares up 2.9% premarket at $74.50. Zeluja demonstrated a statistically significant and clinically meaningful progression-free survival benefit wi...
• PRIME study demonstrates that niraparib treatment had a clinically meaningful and statistically significant benefit in improving progression-free survival in the overall study population regardless of biomarker status when compared to placebo •...
SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following vir...
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today that it has appointed Richard Gaynor, M.D., to its Board of Direc...
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the first patient has been dosed in the Greater China portio...
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the first patient has been treated in the Greater China port...
Zai will have greater China rights to two Blueprint next-gen EGFR candidates aimed at non-small cell lung cancer (NSCLC), which Blueprint says have first-in-class potential. Earlier this year, I-Mab started a pivotal China Phase III trial of eftansomatropin alfa as a weekly treatment ...
Shares of clinical-stage biotech Karuna Therapeutics (NASDAQ: KRTX) are down by a hefty 10% through the first four days of trading this week, according to data from S&P Global Market Intelligence . Karuna's shares started to slide earlier this week after the company announce...
Zai Lab (NASDAQ:ZLAB) announces that the first patient with primary immune thrombocytopenia (ITP) was treated with efgartigimod in Greater China as part of the global registrational ADVANCE-SC Phase 3 study. The ADVANCE-SC study is a randomized, double-blind, placebo-controlled, mul...
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), is a patient-focused, innovative, commercial-stage, global biopharmaceutical company. The company announced today that the first patient with primary immune thrombo...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...